DESTINY-Breast03 Phase 3 Study Results
Subgroup Analysis: PFS in HR+
DESTINY-Breast04
Daiichi-Sankyo
No. of Events/No. of Patients
T-DXd
TPC
PFS, median (95% CI), mo
T-DXd
Hazard Ratio for Disease Progression or Death (95% CI)
TPC
Prior CDK4/6 inhibitors
Yes
No
IHC status
149/233
74/115
10.0 (8.3-11.4)
5.4 (4.0-7.8)
0.55 (0.42-0.73)
60/96
35/47
11.7 (9.5-17.7)
5.9 (4.3-8.2)
0.42 (0.28-0.64)
IHC 1+
119/192
66/96
10.3 (8.6-12.3)
5.3 (4.1-7.8)
0.48 (0.35-0.65)
IHC 2+/ISH-
92/139
44/67
10.1 (8.2-12.2)
5.9 (4.3-7.9)
0.55 (0.38-0.80)
Prior lines of chemotherapy
1
129/203
63/93
10.9 (8.5-12.3)
6.8 (4.5-8.2)
0.54 (0.40-0.73)
≥2
81/127
47/69
9.9 (8.3-11.7)
4.6 (2.8-6.2)
0.47 (0.33-0.68)
Age
<65 years
170/260
79/120
9.8 (8.4-11.3)
5.4 (4.1-7.8)
0.51 (0.39-0.67)
≥65 years
41/71
31/43
12.0 (9.5-14.7)
5.6 (4.3-10.8)
0.47 (0.29-0.77)
Race
White
100/156
43/78
10.0 (8.5-12.2)
7.1 (4.0-10.0)
0.64 (0.44-0.91)
Asian
83/131
54/66
11.0 (8.4-13.8)
4.8 (4.2-6.4)
0.40 (0.28-0.56)
Other
25/37
11/16
6.0 (5.4-10.5)
7.0 (1.4-11.0)
0.83 (0.41-1.69)
Region
Asia
81/128
48/60
10.9 (8.4-14.7)
5.3 (4.2-6.8)
0.41 (0.28-0.58)
Europe and Israel
90/149
44/73
10.8 (8.5-13.0)
7.1 (3.0-10.7)
0.62 (0.43-0.89)
North America
40/54
18/30
8.5 (6.3-11.3)
4.5 (2.9-8.2)
0.54 (0.30-0.97)
ECOG performance status
0
116/187
55/95
10.9 (9.5-13.0)
7.0 (4.2-8.5)
1
95/144
55/68
9.7 (7.3-11.5)
4.6 (2.9-6.2)
Visceral disease at baseline
Yes
No
196/298
15/33
100/146
10/17
9.8 (8.5-11.1)
17.9 (10.9-26.4)
5.8 (4.4-7.1)
4.5 (1.6-12.4)
0.56 (0.40-0.77)
0.45 (0.32-0.64)
0.54 (0.42-0.69)
0.23 (0.09-0.55)
0.0
0.5
1.0
1.5
2.0
Favors T-DXd
Favors TPC
PFS by blinded independent central review. Based on derived data, which include protocol deviations.
CDK, cyclin-dependent kinase; ECOG, Eastern Cooperative Oncology Group; HR, hormone receptor; IHC, immunohistochemistry; ISH, in situ hybridization; PFS, progression-free survival; T-DXd, trastuzumab deruxtecan; TPC, treatment of physician's choice.
ASCO 2022 #LBA3 Plenary Session
15View entire presentation